Fri, Aug 29, 2014, 8:31 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Zalicus Inc. Message Board

  • wildbullus wildbullus Aug 1, 2013 4:47 PM Flag

    Z944 P1b will start soon!

    Advancing Z944, a novel oral T-type calcium channel (Cav 3.1-3.3) blocker, into further clinical development for the treatment of pain in the third quarter of 2013. The planned Phase 1b study is a state-of-the-art experimental clinical model utilizing Laser-Evoked-Potentials (LEP) to provide an efficient and objective assessment of the activity of Z944 in an induced neuropathic pain state. Results from the LEP study can further inform Zalicus’s development plans for Z944 in a variety of potential pain indications.

    Sentiment: Hold

    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.180.00(0.00%)Jul 15 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.